Literature DB >> 942883

The current status of angiography in the evaluation of cancer patients.

S R Reuter.   

Abstract

Angiography has maintained a central role in the preoperative evaluation of patients with both benign and malignant tumors. A great deal of experience has accumulated with the method and the angiographic appearance of most tumors is well established. Although most cancer patients are first evaluated by less invasive techniques,angiography remains the most accurate method for the diagnosis of tumors of the liver and pancreas. In those patients in whom excision of a malignancy is considered, angiograms should be used preoperatively to assess both the resectability and curability of the lesion. In patients with carcinoma of the lung or esophagus invading the azygos vein or in patients with pancreatic carcinoma invading the visceral veins, needless radical operative procedures can be avoided. Finally, as angiographers are becoming more therapy-oriented, the palliative effects of selective arterial embolization with radioactive and infarcting materials are being evaluated.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 942883     DOI: 10.1002/1097-0142(197601)37:1+<532::aid-cncr2820370718>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis.

Authors:  Haohao Lu; Chuansheng Zheng; Bin Liang; Bin Xiong
Journal:  BMC Gastroenterol       Date:  2021-06-11       Impact factor: 3.067

2.  Transcatheter arterial chemoembolization: history for more than 30 years.

Authors:  Yong-Song Guan; Qing He; Ming-Quan Wang
Journal:  ISRN Gastroenterol       Date:  2012-08-26

Review 3.  Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.

Authors:  Edward Wolfgang Lee; Sarah Khan
Journal:  Clin Mol Hepatol       Date:  2017-11-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.